A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

Abstract Purpose 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a phosphoramidate nucleotide analog of fluorodeoxyurid...

Full description

Bibliographic Details
Main Authors: Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans, Sarah P. Blagden
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
NUC-3373
5-FU
5-fluorouracil
Fluoropyrimidines
Thymidylate synthase
Resistant cancer
Online Access:https://doi.org/10.1186/s13046-024-03010-1

Internet

https://doi.org/10.1186/s13046-024-03010-1

Similar Items